Source comparison
Melanotan-2 Interactions: Drug Class Comparison
Before interpreting results, understanding how different drug classes interact with MT-2's receptor activity clarifies which combinations require protocol adjustments and which present manageable overlap. Antihypertensives (ACE inhibitors, beta-blockers, CCBs)
This comparison does not assign a generated winner or score.
- Before interpreting results, understanding how different drug classes interact with MT-2's receptor activity clarifies which combinations require protocol adjustments and which present manageable overlap.
- Antihypertensives (ACE inhibitors, beta-blockers, CCBs)
- MT-2's MC4R-driven sympathetic activation opposes blood pressure reduction
- Moderate. Pressor effect reduces antihypertensive efficacy by 15–30% in preclinical models
- Blood pressure endpoints show attenuated response to test agent
- 24-hour washout between MT-2 and BP measurements; monitor vitals at baseline, 1hr, 6hr post-MT-2
- High interaction significance. MT-2's pressor activity is a confounding variable for any cardiovascular endpoint
- Phosphodiesterase-5 Inhibitors (sildenafil, tadalafil)
- Additive pro-erectile effects. MT-2 increases central arousal via MC4R; PDE5-Is enhance peripheral cGMP-mediated smooth muscle relaxation
- Low to Moderate. Hypotension risk increases if nitrates or alpha-blockers are also present
- Sexual behavior and vascular reactivity endpoints amplified; erectile response shows synergistic enhancement
- Separate dosing by 12–24 hours if studying isolated effects; if studying combination therapy, document additive cardiovascular changes
- Mechanistically predictable interaction. Beneficial for ED research, but requires hypotension monitoring in multi-drug protocols
- GLP-1 Receptor Agonists (semaglutide, tirzepatide)
- Overlapping appetite suppression. MT-2 acts via MC4R in hypothalamus; GLP-1 agonists slow gastric emptying and enhance satiety signaling
- Minimal cardiovascular overlap
- Appetite and food intake endpoints show additive suppression; weight loss and metabolic rate measurements confounded
- Establish MT-2-free baseline for appetite endpoints; use crossover design to isolate each agent's contribution
- Moderate interaction significance. Both agents suppress appetite through distinct but convergent pathways
- Melanocortin Receptor Modulators (PT-141, setmelanotide, Melanotan-1)
- Receptor competition or redundant activation at MC1R, MC3R, MC4R
- Variable. Depends on receptor subtype selectivity
- Redundant receptor occupancy reduces incremental effect; off-target activity increases with non-selective agonists
- Avoid concurrent dosing of non-selective agonists; use receptor-selective agents to isolate specific endpoints
- High interaction significance. Receptor saturation limits additional benefit and increases adverse event probability
- Nitrates (nitroglycerin) and Alpha-Blockers (doxazosin, tamsulosin)
- Additive hypotensive effects. MT-2 lowers systemic vascular resistance via nitric oxide modulation; nitrates and alpha-blockers also reduce vascular tone
- High. Severe hypotension possible with concurrent use
- Blood pressure and orthostatic tolerance endpoints unreliable
- Do not combine in research protocols; if unavoidable, continuous hemodynamic monitoring required
- Contraindicated combination. Hypotension risk outweighs research benefit in most contexts